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Abstract
Recent data have demonstrated no survival benefit to immediate completion lymph node dissection (CLND) for positive 
sentinel node (SN) disease in melanoma. It is important to identify parameters in positive SNs, which predict prognosis in 
melanoma patients. These might provide prognostic value in staging systems and risk models by guiding high-risk patients’ 
adjuvant therapy in clinical practice. In this retrospective study of university hospital melanoma database we analyzed tumor 
burden and prognosis in patients with positive SNs. Patients were stratified by the diameter of tumor deposit, distribution 
of metastatic focus in SN, ulceration and number of metastatic SNs. These were incorporated in Cox proportional hazard 
regression models. Predictive ability was assessed using Akaike information criterion and Harrell’s concordance index. 
A total of 110 patients had positive SN and 104 underwent CLND. Twenty-two (21%) patients had non-SN metastatic 
disease on CLND. The 5-year melanoma specific survival for CLND-negative patients was 5.00 years (IQR 3.23–5.00, 
range 0.72–5.00) compared to 3.69 (IQR 2.28–4.72, range 1.01–5.00) years in CLND-positive patients (HR 2.82 (95% CI 
1.17–6.76, p = 0.020).The models incorporating distribution of metastatic focus and the largest tumor deposit in SN had 
highest predictive ability. According to Cox proportional hazard regression models, information criterions and c-index, the 
diameter of tumor deposit > 4 mm with multifocal location in SN despite of number of metastatic SN were the most important 
parameters. According to the diameter of tumor deposit and distribution of metastatic focus in SN, adequate stratification of 
positive SN patients was possible and risk classes for patients were identified.
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Abbreviations
CLND  Completion lymph node dissection
SN  Sentinel node
SNB  Sentinel node biopsy
SSM  Superficial spreading melanoma
NM  Nodular melanoma
LMM  Lentigo maligna melanoma
AM  Acral melanoma
MSS  Melanoma specific survival
NSN  Non-sentinel node
Introduction
The standard treatment of melanoma is a wide local excision 
of primary tumor and sentinel node biopsy (SNB) for stag-
ing purposes [1]. The utility of SNB correlates with depth 
of invasion of the primary tumor and is a routine manage-
ment in patients with melanoma thicker than 1 mm and may 
be considered for thin lesions with high-risk characteristics 
(e.g. ulceration) [2].
Completion lymph node dissection (CLND) has been 
the standard management approach following positive SNB 
for melanoma. However, with publications of the German 
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Dermatologic Cooperative Oncology Group (DeCOG) trial 
[3] and Multicenter Selective Lymphadenectomy-2 trial 
(MSLT-2) [4], indications for CLND continue to evolve. 
The latest DeCOG trial results with 72 months follow-up 
have shown that CLND compared to observation in patients 
with positive SNB is not associated with increased overall 
survival [5]. MSLT-2 showed that CLND provides prognos-
tic information as well as improved regional disease control 
[4], while final analysis of DeCOG-SLT trial concluded that 
a therapeutic benefit for CLND could not be demonstrated 
[5]. However, there are differences in SNB protocols and 
clinicopathologic features of the patient cohorts between 
centres. Even the conclusions of DeCOG-SLT and MSLT-2 
trials have been suggested to be limited by study populations 
which overall harbored a lower burden of SN disease [6].
Clinical practice has changed dramatically since CLND 
is expected no longer to be standard procedure after a posi-
tive SNB. However, there is a 20% chance of having non-SN 
(NSN) positivity in CLND after a positive SNB [7]. In cuta-
neous melanoma patients, the presence of disease in NSNs 
has been found to be a strong independent adverse prognos-
tic factor for survival [8]. Without CLND the pathologic 
status of NSNs is not revealed. The systemic therapy for 
melanoma is evolving rapidly. These therapies have signifi-
cantly improved the perspective of patients with stage IV 
melanoma. Since CLND is no longer performed routinely in 
stage III melanoma, there is a vacuum for these patients for 
adjuvant therapy. Positive results have been published from 
clinical trials evaluating the systemic therapy potential also 
in high-risk stage III melanoma [9]. Thus, it is important 
to explore variables associated with SN positivity and find 
patients that are at high-risk of recurrence and/or melanoma-
specific death by using information retrieved from the pri-
mary melanoma and SNB.
The prior research has identified several micromorpho-
metric criteria to evaluate tumor burden in SN, and a large 
variety of cut-off metastasis dimensional limits have been 
studied. Currently, the maximum diameter of the largest 
tumor deposit (Rotterdam classification) and the intranodal 
location of SN tumor burden (Dewar classification) are the 
most common recommended parameters to evaluate tumor 
burden in SN [1]. Microscopic SN tumor burden (> 1 mm) 
has already been implemented as an inclusion criterion in 
some clinical trials. Although this parameter is not yet a for-
mal staging criterion for the N category in the eight edition, 
documentation of SN tumor burden is an important prog-
nostic factor that will likely guide the development of future 
prognostic models and validated clinical tools for patients 
with regional metastatic disease [10]. In various studies, also 
other parameters have been studied [1, 8, 9, 11–14].
Our study sought to determine an adequate stratification 
of positive SN patients based on the maximum diameter of 
the largest tumor deposit, distribution of metastatic focus in 
SN, ulceration of primary tumor and number of metastatic 
SN. These parameters might provide accurate prognostic 
value in staging systems and risk models by guiding high-
risk patients’ treatment protocols.
Materials and methods
According to Tampere university hospital melanoma data-
base, 506 patients underwent successful SNB for cutane-
ous melanoma between 2006 and 2016. In this retrospec-
tive study, we included 110 patients who had positive SNB. 
Permission to access the clinical records of the melanoma 
patients for the study was obtained from the scientific center 
of Tampere University Hospital. In our skin cancer unit, 
we have 10-year follow-up program (three clinical check-up 
visits/year) for the melanoma patients with metastasis in SN. 
In this study, we included patients with new melanoma diag-
nosed and operated between 1.1.2006 and 31.12.2016. The 
follow-up was performed until 31.1.2019. Patients were cen-
sored from survival analyses at 5-year time point. In future, 
we will continue the follow-up with these patients to have 
10-year follow-up for all.
Retrospective review of records was performed to deter-
mine following information: age, gender, primary tumor site 
(head/neck, trunk, upper limb, lower limb), tumor charac-
teristics (Breslow thickness, ulceration, subtype superficial 
spreading melanoma, (SSM), nodular melanoma (NM), len-
tigo maligna melanoma (LMM) and acral melanoma (AM)) 
and time of diagnosis. Clinical outcomes regarding sentinel 
node (SN) included the lymph node basin (cervical, axillary, 
inguinal and bi-locational), maximum size (in millimeters) 
of largest tumor deposit in SN, distribution of metastatic foci 
in SN subcapsular, parenchymal and multifocal, number of 
SNs removed and number of metastatic SN. Clinical out-
comes regarding CLND included number of nodes harvested 
in CLND and number of metastatic lymph nodes found on 
CLND. Time of the recurrence was recorded as well as time 
of death and reason for death (melanoma, other).
Stratifying patients according to the largest tumor 
deposit (< 1  mm, 1–4  mm or > 4  mm), distribution of 
metastatic focus in SN [unifocal (subcapsular or paren-
chymal) or multifocal] and ulceration (absent or present) 
resulted in three categories of parameter pairs: ulceration 
and distribution of metastatic focus, ulceration and larg-
est tumor deposit, distribution of metastatic focus and 
largest tumor deposit. Each three categories were further 
divided to groups: group 1 (ulceration absent and tumor 
deposit < 1  mm/1–4  mm/ > 4  mm, ulceration present 
and tumor deposit < 1  mm/1–4  mm/ > 4  mm), group 2 
(ulceration absent and tumor distribution uni-or multifo-
cal, ulceration present and tumor distribution uni-or mul-
tifocal), group 3 (tumor distribution unifocal and tumor 
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Table 1  Patient and tumor 
characteristics overall and by 
CLND status
CLND negative n = 82 CLND positive (n = 22) p-value
n (%) n (%)
Age (years), mean (SD) 66.5 (12.9) 63.4 (16.5) 0.349
Sex, n (%) 0.107
 Men 48 (59) 17 (77)
 Women 34 (41) 5 (23)
Ulceration, n (%) 0.222
 No 31 (38) 5 (23)
 Yes 51 (62) 17 (77)
Tumor thickness (mm), n (%) 0.052
 Br < 2 mm 24 (29) 2 (9)
 Br ≥ 2 mm 58 (71) 20 (91)
Subtype, n (%) 0.064
 SSM 45 (55) 13 (59)
 NM 33 (40) 5 (23)
 AM 4 (5) 4 (18)
Tumor location, n (%) 0.102
 Head and neck 7 (8) 6 (27)
 Trunk 36 (44) 8 (36)
 Upper limb 18 (22) 2 (9)
 Lower limb 21 (26) 6 (27)
Number of SN removed, n (%) 0.899
 1 14 (17) 4 (18)
 2 30 (37) 9 (41)
 ≥ 3 38 (46) 9 (41)
Sentinel node location, n (%) 0.125
 Axillary 39 (48) 6 (27)
 Inguinal 24 (29) 6 (27)
 Cervical 8 (10) 6 (27)
 Bi-locational 11 (13) 4 (18)
Interferon 29 (35) 9 (41) 0.632
Size of largest metastatic focus, n (%) 0.349
 < 1 mm 27 (33) 5 (23)
 1–4 mm 34 (41) 8 (36)
 > 4 mm 21 (26) 9 (41)
Distribution of metastatic focus/foci 0.240
 Subcapsular 32 (39) 6 (27)
 Parenchymal 31 (38) 7 (32)
 Multifocal 19 (23) 9 (41)
Number of metastatic sentinel nodes 0.206
 One 65 (79) 14 (64)
 Two 14 (17) 6 (27)
 Three or more 3 (4) 2 (9)
Type of recurrence 0.600
 No recurrence 43 (52) 9 (41)
 Local recurrence 7 (8) 3 (14)
 Regional recurrence 7 (8) 3 (14)
 Distant metastasis 25 (31) 7 (32)
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deposit < 1 mm/1–4 mm/> 4 mm, tumor distribution multi-
focal and tumor deposit < 1 mm/1–4 mm/> 4 mm).
We further analyzed parameter pairs of the largest tumor 
deposit (< 1  mm, 1–4  mm or > 4  mm)/subcapsular and 
parenchymal location of metastatic focus (group 4) and the 
largest tumor deposit (< 1 mm, 1–4 mm or > 4 mm)/number 
of metastatic SN (1 or > 1) (group 5).
SNB was performed for all patients with a melanoma with 
Breslow thickness > 1 mm or 0.75–1 mm with ulceration 
and/or mitotic activity > 1/mm2. A preoperative lymphoscin-
tigraphy was performed for all patients using 99mTc labeled 
human albumin colloid injected intra-dermally. Patent blue 
was used until October 2013. Single-photon emission com-
puterized tomography/computed tomography (SPECT/CT) 
was performed for all melanoma patients preoperatively 
starting in October 2013. Intraoperative identification of the 
SN was done with a handheld gamma probe. Radioactive 
nodes that had count > 10% of the most radioactive node 
were also considered as SNs. Histopathologic analysis of SN 
consisted of sectioning and staining with hematoxylin and 
eosin. The immunohistochemical markers S-100, Melan-A 
and HMB-4 were used routinely.
Statistical analysis
Predictive factors for SN were calculated by univariable 
using Mann–Whitney test, Pearson chi-square test or Fish-
er’s exact test. Disease-free survival (DFS) was defined as 
the time between the time of diagnosis and detected recur-
rence. Survival was calculated from the time of diagnosis to 
death, either from melanoma (melanoma-specific survival, 
MSS) or other causes. Time-to-event analyses were per-
formed using Cox proportional hazard regression analysis. 
A p-value of < 0.05 was considered significant. Harrell’s 
concordance index (c-index) and the Akaike information cri-
terion (AIC) values were analysed to compare the predictive 
ability of the different Cox regression models [15, 16]. A 
higher c-index and lower AIC value indicate a better model 
for predicting outcome. All analyses were performed using 
IBM SPSS Statistics for Windows, version 25.0 software 
(IBM Corp., Armonk, NY) and R (version 3.6.1, R Founda-
tion for Statistical Computing, Vienna, Austria, 2019).
Results
From 2006 to 2016, 506 patients [274 (54%) men and 232 
(46%) women] underwent SNB. A total of 110 patients out 
of 506 (22%) had metastasis in SNB and were included in 
the study. Of these 110 SNB positive cases, six (5%) had 
isolated tumor cells (ITC) and CLND was not performed. 
Follow-up was performed until 31.1.2019. Median follow-
up time (n = 104) 4.71 (IQR 2.92–7.85, range 0.72–12.02), 
CLND negative n = 82 Md 5.29 (IQR 3.23–8.22, range 
0.72–12.02) and CLND positive n = 22 Md 3.69 (IQR 
2.28–4.90, range 1.01–9.21). There was a difference in the 
length of follow-up period between subgroups (Mann–Whit-
ney test p = 0.016).
CLND‑positive compared with CLND‑negative cases
We compared the characteristics of the CLND-positive 
patients and tumors to those of the CLND-negative group 
(Table 1). CLND-positive patients were slightly younger 
(p = 0.349), more male predominant p = 0.107), had more 
commonly melanomas thicker than 2 mm (p = 0.052) and 
ulcerated melanomas (p = 0.222) than CLND-negative 
patients. SSM was the most common subtype in both 
groups, but NM was more common and AM less common 
in CLND-negative patients than in CLND-positive patients 
(p = 0.064). Trunk and lower limb were the most common 
locations of melanoma in both groups, but head/neck area 
was more common and upper limb less common location 
Table 1  (continued)
CLND negative n = 82 CLND positive (n = 22) p-value
n (%) n (%)
Exitus during follow-up, n (%) 0.411
 Alive 49 (60) 10 (46)
 Of melanoma 22 (27) 9 (41)
  Of other reasons 11 (13) 3 (14)
 Follow-up time (years), median (range) 5.29 (0.72–12.02) 3.69 (1.01–9.21) 0.016
Univariable analyses were performed using Mann–Whitney test, Pearson chi-square or Fisher’s exact test. 
In multivariable logistic regression analysis, adjusting factors (age, sex, categorized tumor thickness and 
tumor location) were included simultaneously into the model. Results were shown by odds ratios (OR) with 
95% confidence intervals (CI)
SSM superficial spreading melanoma, NM nodular melanoma, AM acral melanoma, CLND positive residual 
disease in lymph nodes in complete lymph node dissection, CLND negative no residual disease in lymph 
nodes in complete lymph node dissection
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in CLND-positive patients (p = 0.102). SN basin was more 
commonly in axillary region and less commonly in cervical 
area in CLND-negative patients compared to CLND-positive 
patients (p = 0.102). Number of SNs removed did not differ 
significantly between groups. Of CLND negative patients, 
29 received interferon treatment compared to nine CLND 
positive patients (p = 0.632). Six patients out of 15 with bi-
locational SN basin had metastases in two basins.
CLND-negative patients had more commonly one meta-
static SN and less commonly two or more metastatic SNs 
than CLND-positives (p = 0.206). SN tumor burden located 
multifocally (p = 0.240) and maximum diameter of the larg-
est tumor deposit > 4 mm (p = 0.349) was more likely in 
CLND-positive patients. Detailed data of CLND-positive 
cases is presented in Table 2.
Recurrence patterns and survival analysis
A half (43/82, 52%) of CLND-negative compared to 41% 
(9/22) of CLND-positive patients did not have recurrence 
during the study period (Table 1). Both groups had equal 
proportion of local and regional recurrences and distant 
metastases. In CLND-positive patients recurrences occurred 
earlier with 5-year disease free survival (DFS) median of 
2.18 years (IQR 0.77–3.75, range 0.30–5.00) compared to 
3.83 years (IQR 1.87–5.00, range 0.15–5.00) in CLND-
negative patients (HR 1.79 (95% CI 0.92–3.45, p = 0.084).
The 5-year melanoma specific survival (MSS) for 
CLND-negative patients was 5.00 years (IQR 3.23–5.00, 
range 0.72–5.00) compared to 3.69 (IQR 2.28–4.72, range 
1.01–5.00) years in CLND-positive patients (HR 2.82 (95% 
CI 1.17–6.76, p = 0.020). The 5-year cumulative proportion 
surviving at time for CLND negative was 80.4% (Std. error 
4.8%) and for CLND positive 41.6% (Std. error 13.8%).
Fig. 1  Five-year melanoma specific survival in group 1 (N = 104). 
In this group, the largest tumor deposit and ulceration status of the 
tumor were incorporated in the model. The Bayesian information cri-
teria of the model was 190.7 and concordance index = 0.387. A total 
of 22 (21.2%) of the patients were deceased
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Stratification models and risk classes
The 5-year MSS was different inside groups. The distribu-
tion, model performance and 5-year MSS per group and the 
corresponding Cox proportional hazard regression models 
are presented in Figs. 1, 2, 3, 4 and 5.
In group 1, patients with tumor deposit < 1 mm and ulcer-
ation in primary tumor had 5-year MSS median of 5.00 years 
(94%) compared to 3.31 years (61%) in patients with tumor 
deposit > 4 mm and ulcerated primary tumor (p = 0.035) 
(Fig. 1). In patients with tumor deposit > 4 mm ulceration 
status of primary tumor did not have influence in survival.
In group 2, patients with unifocal distribution of tumor 
deposit and primary melanoma without ulceration had 5-year 
MSS median of 5.00 years (91%) compared to 4.03 years 
(63%) in patients with ulcerated primary tumor and multifo-
cal distribution of tumor deposit in SN (p = 0.040) (Fig. 2). 
Multifocality clearly influenced the prognosis despite of 
ulceration status of primary tumor.
In group 3, patients with unifocal tumor distribution and 
tumor deposit < 1 mm had 5-year MSS median of 5.00 years 
(97%) compared to 3.49 years (40%) in patients with mul-
tifocal tumor distribution and tumor deposit > 4 mm in SN 
(p = 0.002) (Fig. 3). Unifocal tumor location seemed to be 
associated with better prognosis.
In group 4, patients with tumor deposit < 1 mm either 
with subcapsular or parenchymal tumor location and patients 
with tumor deposit 1–4 mm with subcapsular location had 
5-year MSS median of 5.0 years (94–100%) compared to 
3.5–4.3 years (67–75%) in patients with parenchymal tumor 
location either tumor deposit with 1–4 mm or > 4 mm. 
Parenchymal location did not worsen the prognosis in 
patients with tumor deposit < 1 mm, but with increasing 
tumor deposit it predicted worse survival. Subcapsular 
Fig. 2  Five-year melanoma specific survival in group 2 (N = 104). 
In this group, the ulceration status of the tumor and distribution of 
metastatic focus in sentinel node were incorporated in the model. 
The Bayesian information criteria of the model was 192.3 and con-
cordance index = 0.670. A total of 22 (21.2%) of the patients were 
deceased
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location seemed to be associated with better prognosis in 
patients with tumor deposit with 1–4 mm.
In group 5, patients with tumor deposit < 1 mm and with 
one metastatic SN had 5-year MSS 5.0 (97%) compared to 
2.6 years (56%) in patients with tumor deposit > 4 mm and 
more than one metastatic SN (p = 0.008). In patients with 
tumor deposit > 4 mm, the number of metastatic SN did not 
have great influence in survival.
According to these differences in survival, we were able 
to find possible risk classes inside groups (low, intermediate 
and high).
Discussion
In this study, we evaluated five models with four param-
eters, including the maximum diameter of the largest tumor 
deposit, distribution of metastatic focus in SN, ulceration of 
primary tumor and number of metastatic SN, in melanoma 
patients with positive SN to investigate the possible relation-
ship with patient survival. We were able to determine an 
adequate stratification and identify risk classes for patients.
SNB is the most accurate staging tool for melanoma 
patients [17]. The 5-year overall survival is about 90% for 
patients with negative SN and 71% for patients with positive 
SN [1]. Approximately 20% of melanoma patients harbor 
Fig. 3  Five-year melanoma specific survival in group 3 (N = 104). In 
this group, the largest tumor deposit and the distribution of metastatic 
focus in sentinel node were incorporated in the model. The Bayes-
ian information criteria of the model was 187.5 and concordance 
index = 0.408. A total of 22 (21.2%) of the patients were deceased
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metastases in NSNs after a positive SNB [18]. In cutaneous 
melanoma patients, the presence of disease in NSNs has 
been found to be a strong independent adverse prognostic 
factor for survival [8]. Also in our study, the worse 5-year 
MSS was also seen in CLND-positive patients compared 
to CLND-negative patients. Positive SNs in two basins has 
been published to be worse prognostic factor [19, 20]. In 
our study, only six patients had positive SN in two basins.
There have been efforts to identify predictors for CLND 
positivity and prognosis focusing on characteristics of the 
SN metastasis and histologic and anatomic characterization 
of the primary tumor, which may carry additional prognostic 
value [11]. In terms of anatomic location, there has been var-
iable reports showing that lower extremity primary tumors 
are more likely than both truncal and head and neck tumors 
in patients with NSN-positivity [21], while other showed 
that primary tumor in limbs conferred to a lower risk of 
NSN-positivity compared to trunk and head and neck [18]. 
In our study, trunk and lower limb were the most common 
locations of melanoma in both groups, but head and neck 
area was more common and upper limb less common loca-
tion in CLND-positive patients. SN basin has also been 
investigated as prognostic parameter of NSN-positivity. It 
has been suggested that axillary bed is less likely than either 
Fig. 4    Five-year melanoma specific survival in group 4 (N = 76). 
In this group, the location of metastatic focus and the largest tumor 
deposit were incorporated in the model. The Bayesian information 
criteria of the model was 90.4 and concordance index = 0.424. A total 
of 11 (10.6%) of the patients were deceased
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groin or cervical basins to yield positive NSNs [14], which 
was also shown in our study.
The most used tumor burden parameters are the maxi-
mum diameter of the SN metastasis and microanatomic loca-
tion of metastasis in the SN [17]. In addition to diameter and 
location, we also incorporated the number of metastatic SNs 
and ulceration of the primary tumor into the models. These 
parameters were included because in overall characteris-
tics of our study cohort by CLND status, CLND-positive 
patients had more commonly ulcerated tumors and more 
than one metastatic SN than CLND-negative patients. Pre-
vious studies have demonstrated that 70%- 80% of patients 
with positive SN will have only a single positive node [12], 
which is in agreement with our study. Patients with a single 
positive node are clinically stage III according to AJCC 8th 
edition and thus candidates for adjuvant immunotherapy, 
but they are suggested to represent the lowest risk group 
for NSN metastases and might be ones in whom adjuvant 
therapy can be safely avoided [10]. In our model incorpo-
rating the number of metastatic SN and maximum diameter 
of tumor deposit, the patients with tumor deposit < 1 mm 
and one metastatic SN had the best 5-year MSS. The diam-
eter of tumor deposit influenced more in prognosis than the 
number of metastatic SN. Number of positive SNs did not 
Fig. 5  Five-year melanoma specific survival in group 5 (N = 104). 
In this group, the number of metastatic sentinel node and the largest 
tumor deposit were incorporated in the model. The Bayesian informa-
tion criteria of the model was 188.9 and concordance index = 0.378. 
A total of 22 (21.2%) of the patients were deceased
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have apparent impact either in prediction of positive NSNs 
in study by Gershenwald et al. [21].
Ulceration is an adverse prognostic factor in cutaneous 
melanoma [10]. It has been shown to be the most impor-
tant predictor of lymphatic involvement especially in thick 
melanomas [13]. Ulceration has also been evaluated in mod-
els associated with prognostic role in melanoma [9, 13]. In 
our study, ulceration was incorporated with tumor deposit 
diameter and distribution in SN. Ulceration predicted worse 
survival in patients with tumor deposit of 1–4 mm, while 
in patients with tumor deposit < 1 mm and > 4 mm ulcera-
tion did not play significant role. In the model incorporating 
ulceration with tumor distribution, the multifocal location of 
tumor deposit influenced more in survival than ulceration. 
In prior studies, primary tumor ulceration had no apparent 
impact either on prediction of positive NSNs [21].
We investigated the combination of the maximum diam-
eter of the SN metastasis and microanatomic location of 
metastasis in the SN in two models. In first model, we incor-
porated maximum diameter of the largest tumor deposit with 
unifocal or multifocal location of tumor deposit tumor in 
SN. In the second model, we further evaluated the model 
incorporating the diameter of tumor deposit and subcap-
sular or parenchymal location of tumor deposit in SN. In 
prior studies, cut points and measures of SN disease burden 
vary with each reported model. We chose 1 mm diameter 
to the cut point because in earlier studies, maximum tumor 
size > 1 mm has been suggested to be the most reliable 
parameter associated with higher NSN-positivity and poorer 
MSS [1, 9, 11, 22]. Multifocal SN tumor deposit location has 
been shown to be independently associated with NSN-pos-
itivity [11, 12] and subcapsular site with positive prognos-
tic significance [1]. In our models, tumor diameter < 1 mm 
was clearly associated with better and diameter > 4 mm to 
poorer survival. In patients with tumor deposit diameter of 
1–4 mm, the tumor distribution seemed to influence more in 
survival. Multifocality and parenchymal location of tumor 
deposit worsen the survival.
In our study, the risk of non SN involvement was higher 
when (1) the primary melanoma is thicker than 2 mm, (2) 
ulcerated, (3) more SNs involved; and (4) the largest meta-
static focus in SN is > 1 mm or (5) is located multifocally or 
in parenchyme. The results of the current study are largely 
consistent with previously published literature. Ulceration of 
primary tumor and number of metastatic SN had less impact in 
stratification, while the combination of the maximum diameter 
of the largest tumor deposit and distribution of metastatic focus 
in SN yielded the best stratification. These parameters might 
provide accurate prognostic value in staging systems and risk 
models by guiding high-risk patients’ treatment protocols and 
finding ones in whom adjuvant therapy can be safely avoided. 
However, stratifying for survival is not necessarily equivalent 
to stratifying for therapeutic benefit. Whether the presented 
risk classes are able to stratify accurately for therapeutic ben-
efit as well, needs to be evaluated. On the other hand, risk strat-
ification can also help to inform the frequency of ultrasound 
nodal surveillance in the SN basin, with lower risk patients 
perhaps requiring less frequent ultrasound imaging and higher 
risk patients requiring a more intense surveillance program.
This study has certain limitations. One of the limitations 
is its retrospective design. The patient cohort upon which the 
model was based consisted of a relatively small cohort. The 
analyses were, however, based on complete case analysis 
without missing data.
Conclusion
In this study, we evaluated our experience of SN-positive 
patients undergoing CLND to identify those at high or 
low risk. By using the easy-to-obtain clinicopathological 
information, including diameter of tumor deposit and dis-
tribution of metastatic focus in SN we were able to identify 
risk classes for patients. SN tumor burden characteriza-
tion provides prognostic information, which is useful in 
patients who do not undergo CLND. These parameters 
might provide accurate prognostic value in staging systems 
and risk models by guiding high-risk patients’ treatment 
protocols and finding ones in whom adjuvant therapy can 
be safely avoided.
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